DigestRedComo funciona
Red
/
Empresas
Me
No verificado

Merck & Co., Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

187 Comunicados de prensa

Ver todos los comunicados de prensa
28/02/2026
Multimedia
Eventos
Industria
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
27/02/2026
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
27/02/2026
Ferias y Congresos
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
25/02/2026
Eventos
Ferias y Congresos
Industria
Análisis de Mercados
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Sanidad
Salud
Farmacéutica
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
24/02/2026
Web y redes sociales
Eventos
Biotecnología
Sanidad
Farmacéutica
Salud
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
23/02/2026
Mercado laboral
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
19/02/2026
Eventos
Industria
Salud
Higiene alimentaria
VIH, SIDA y enfermedades autoinmunes
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
12/02/2026
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
11/02/2026
Oncología
Venta al público/Minorista
Salud
Higiene alimentaria
Suministros/Electrodomésticos
Farmacéutica
Biotecnología
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
03/02/2026
Biotecnología
Sanidad
Farmacéutica
Salud
Web y redes sociales
Telefonía
Mercado de valores
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0